Clinical trials: Diffuse Parenchymal Lung Diseases
Lung Cancer, Interstitial Lung Disease
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease
In this double-blind phase II randomized controlled trial, patients with lung cancer or ≤2 oligometastatic pulmonary lesions and a concomitant diagnosis of ILD who are planned for radical Radiation Therapy (RT) will be randomized…
- Trial name
- RESPIRE-ILD (NCT05986318)
- Testing
- N-Acetyl cysteine, Dexamethasone Oral, Radiation Therapy
- Where
- 4 sites in Canada
- Volunteers
- 98 people
- Sponsor
- David Palma
Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of interstitial lung disease. Between 2% and 20% of patients with IPF have a family history of the disease, which is considered the strongest risk…
- Trial name
- GENESI (NCT06521125)
- Testing
- High resolution Computed Tomography (HRCT) scans of the Chest, Pulmonary Function Testing (PFTs), Digital lung sounds auscultation
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Inspiration Expiration Thoracic TDM Sequences of Patients With Diffuse Interstitial Lung Disease (DIP)
Digital Modeling of Thoracic CT and Pulmonary Fibrosis
Currently, to our knowledge, there is little data on the combination of tools based on a similar concept to understand and evaluate ILDs.
- Trial name
- MLQ-CT (NCT06618924)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Intersticial Lung Disease
Can High-Flow Oxygen Therapy Improve Oxygenation During Exercise in ILD Patients?
Objectives: 1.- To compare the level of oxygenation achieved during muscular training with conventional oxygen systems (nasal cannulas) versus nasal High-flow oxygen therapy.
- Trial name
- NCT03287713
- Testing
- oxygen therapy
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Fibrotic Interstitial Lung Disease
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
Early antifibrotic therapy for f-ILD
- Trial name
- NCT07141810
- Testing
- Antifibrotic drugs (nidanib or pirfenidone)
- Volunteers
- 104 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Asthma, Pulmonary Fibrosis
Segmental Bronchoalveolar Lavage
Bronchoalveolar lavage (BAL) is a diagnostic and therapeutic procedure conducted by placing a small fiberoptic scope into the lung of a patient, and injecting sterile water (saline) into the lung and removing the fluid.
- Trial name
- NCT00001618
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Behcet's Disease, Churg-Strauss Syndrome
VCRC Patient Contact Registry Patient-Reported Data Validation Study
The purpose of this study is to provide validation of patient-reported data in the VCRC Patient Contact Registry by comparing patient-reported data with data provided by the physician who is the primary provider caring for the…
- Conditions
- Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis
- Trial name
- NCT02190942
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- University of South Florida
Pneumonitis, Interstitial, COVID-19
TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia
Multifocal interstitial pneumonia represents the most common cause of admission in intensive care units and death in SARS-CoV2 infections.
- Trial name
- TOFACoV-2 (NCT04390061)
- Testing
- Tofacitinib, Hydroxychloroquine
- Volunteers
- 116 people
- Sponsor
- Università Politecnica delle Marche
Influenza, Pneumonia, Viral
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
Influenza A (H1N1) v2009 infection was responsible throughout the world of viral pneumonia and severe pulmonary edema requiring rescue therapeutics such as extracorporeal oxygenation.
- Conditions
- Influenza, Pneumonia, Viral, Pulmonary Fibrosis, Quality of Life
- Trial name
- RESPIFLU (NCT01271842)
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Lung Diseases, Obstructive, Sarcoidosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid…
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma
- Trial name
- ICEtheBAD (NCT00747461)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Rheumatoid Lung, Rheumatoid Arthritis
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression
BERTHA study´s primary objective is to characterize Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) progression and to define a combination of biomarkers, genetic and clinical variables capable of identifying…
- Conditions
- Rheumatoid Lung, Rheumatoid Arthritis, Interstitial Lung Disease, Pulmonary Fibrosis
- Trial name
- BERTHA (NCT04136223)
- Where
- 5 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Hospital do Coracao
Radiation; Adverse Effect, Pneumonitis
Predictors of Radiation Pneumonitis in Locally Advanced Lung Cancer Treated With Chemoradiation
Lung cancer [LC] is the leading cause of cancer death worldwide. The standard treatment of locally advanced lung cancer unresectable or marginally resectable is combination therapy with radical or preoperative chemoradiation.
- Trial name
- NCT01580579
- Where
- Mexico
- Volunteers
- 62 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting.
- Conditions
- Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- NCT00625079
- Testing
- sildenafil
- Where
- United States
- Sponsor
- University of California, Los Angeles
Pulmonary Fibrosis, Pulmonary Disease, Chronic Obstructive
Exercise Tolerance and Lower-limb Muscle Power in Patients With Chronic Respiratory Disease
The aim of this study is to validate the six minute Stepper Test (6MST) and the 5-repetition chair lift test (5STS) as measures of exercise tolerance and muscle power, respectively, in patients with chronic respiratory disease.
- Trial name
- VTEP (NCT06124859)
- Testing
- Functional capacity tests
- Where
- 2 sites in Canada, France
- Volunteers
- 30 people
- Sponsor
- Lille Catholic University
Pulmonary Hypertension, COPD
Integrating ePReBMs From Phoenix in Respiratory Diseases
Participants with respiratory disease experience often a worsening of their condition, with increasing symptoms such as cough and shortness of breath.
- Conditions
- Pulmonary Hypertension, COPD, Interstitial Lung Disease, Healthy Volunteers
- Trial name
- NCT05827302
- Testing
- Health Gauge AI-Based Wearable Device - Model: Phoenix
- Where
- Canada
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Healthy Participants
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
This is a study in healthy participants designed to assess the effect of multiple doses of itraconazole, gemfibrozil, or carbamazepine on the drug levels of a single-dose of BMS-986278.
- Trial name
- NCT05932303
- Testing
- BMS-986278, Itraconazole, Gemfibrozil
- Where
- Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis (IPF)
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF…
- Trial name
- ASPIRE (NCT06588686)
- Testing
- Buloxibutid
- Where
- 104 sites in United States, Argentina and 12 more
- Volunteers
- 378 people
- Sponsor
- Vicore Pharma AB
Systemic Sclerosis, Interstitial Lung Disease
Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and…
- Trial name
- SCLEROPIDEVOL (NCT05345795)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Central Hospital, Nancy, France
Lung Diseases, Interstitial (in Pediatric Populations), Childhood Interstitial Lung Disease (chILD)
A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)
This Expanded Access Program (EAP) is intended to facilitate the availability of OFEV® (nintedanib) to children and adolescents with chronic fibrosing interstitial lung disease (ILD) on top of current standard of care treatment…
- Trial name
- NCT05624281
- Testing
- nintedanib
- Sponsor
- Boehringer Ingelheim
Interstitial Lung Disease, Pulmonary Hypertension
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis.
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis
- Trial name
- NCT07821398
- Testing
- Hyperpolarized 129 Xenon Gas
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.